BioXplor was founded in January 2017 and is a UC Berkeley Skydeck and Merck accelerator company. Pavels Kartasevs, MEng (Computer Engineering), MSc (Bioinformatics) is CTO, and has a rare combined background in high performance computing, bioinformatics and software engineering, having worked in research at Cranfield University and previously led technology at another startup in London, prior to BioXplor. Anna O'Leary, BA (Economics & Finance) is COO, and has started businesses herself as well as having won management awards for change management and team building, and she also established the first student partnership between University of Limerick and UBS Global Markets in the US. Mark has a commercial background in emerging biotechnology and gene-editing and a research background in adult stem cell-based gene therapy, protein-protein interaction screening, and mES transgenic model development. He was previously Associate Director, Emerging Biotechnology Initiative at Merck KgaA, where he ran their first grant program targeting high potential biotech startups in Europe.
BioXplor has formed a multi-disciplinary team of over 20 academic and industry expert advisors, employees, and consultants to enable cutting-edge technology development and data-driven biomedical discoveries. The team is based in the USA and Europe, and uniquely combines expertise in software and data engineering, high-performance computing, machine learning, natural language processing, biomedical science, clinical trials, & drug discovery.